Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Business Wire

28 Jul 2026, 00:40 UTC · 2h ago

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law

What the story claims

1 claim · each scored for market impact

What matters in this story

1
SBS Law is initiating a fraud investigation into Zevra Therapeutics, Inc. ($ZVRA). — Allegations of corporate fraud typically trigger immediate sell-offs and increase the risk profile of the equity.
-0.80

Which stocks this story touches

How each ticker is affected

ZVRA-1.00
The company is the subject of a fraud investigation.

Read original · https://www.businesswire.com/news/home/20260727201341/en/ZVRA-Investors-Have-Opportunity-to-Join-Zevra-Therapeutics-Inc.-Fraud-Investigation-with-SBS-Law/

6 related stories

Zacks Investment Research
4h ago
Adma Biologics (ADMA) Rises Higher Than Market: Key Facts
- biotech
- pharmaceuticals
Read

ZVRA Investors Have Oppor… — ZVRA -1.00 | NewsImpactScreener

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law

What matters in this story

How each ticker is affected

Adma Biologics (ADMA) Rises Higher Than Market: Key Facts

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law

What matters in this story

How each ticker is affected

Adma Biologics (ADMA) Rises Higher Than Market: Key Facts

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Regeneron Pharmaceuticals (NASDAQ: REGN) Investors Who Suffered Losses May Be Eligible to Participate in the Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses

Kaplan Fox Urges Investors of Erasca, Inc. (ERAS) with Significant Losses to Seek a Leadership Role Before August 10, 2026

ERAS Stock Drop: If You Incurred Significant Losses in Erasca, Inc., Contact Robbins LLP for Information About Recovering Your Losses

CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law

What matters in this story

How each ticker is affected

Next reads from the same story arc

Adma Biologics (ADMA) Rises Higher Than Market: Key Facts

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law

What matters in this story

How each ticker is affected

Next reads from the same story arc

Adma Biologics (ADMA) Rises Higher Than Market: Key Facts

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Regeneron Pharmaceuticals (NASDAQ: REGN) Investors Who Suffered Losses May Be Eligible to Participate in the Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses

Kaplan Fox Urges Investors of Erasca, Inc. (ERAS) with Significant Losses to Seek a Leadership Role Before August 10, 2026

ERAS Stock Drop: If You Incurred Significant Losses in Erasca, Inc., Contact Robbins LLP for Information About Recovering Your Losses

CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm